液体生検用循環バイオマーカーの世界市場 2020年

• 英文タイトル：Global Circulating Biomarker for Liquid Biopsy Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：GIR201113869 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本書では、液体生検用循環バイオマーカーの世界市場を調査対象にし、液体生検用循環バイオマーカーの市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（循環腫瘍細胞（CTC）、循環腫瘍DNA（ctDNA）、無細胞DNA（cfDNA）、細胞外小胞（EV）、その他）、用途別分析（早期がん検診、治療法選択、治療モニタリング、再発モニタリング整形外科）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Abbott Laboratories、Fluxion Biosciences、Epigenomics AG、Becton, Dickinson and Company、Affymetrix、GE Healthcare、Biocept、Agilent Technologies ・企業別売上、市場シェア ・液体生検用循環バイオマーカーの地域別市場分析 ・液体生検用循環バイオマーカーの北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・液体生検用循環バイオマーカーのヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・液体生検用循環バイオマーカーのアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・液体生検用循環バイオマーカーの南米市場規模2015-2020：ブラジル、アルゼンチンなど ・液体生検用循環バイオマーカーの中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・液体生検用循環バイオマーカーの種類別市場規模2015-2020：循環腫瘍細胞（CTC）、循環腫瘍DNA（ctDNA）、無細胞DNA（cfDNA）、細胞外小胞（EV）、その他 ・液体生検用循環バイオマーカーの用途別市場規模2015-2020：早期がん検診、治療法選択、治療モニタリング、再発モニタリング整形外科 ・液体生検用循環バイオマーカーの世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論

Market Overview
The global Circulating Biomarker for Liquid Biopsy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Circulating Biomarker for Liquid Biopsy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Circulating Biomarker for Liquid Biopsy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Circulating Biomarker for Liquid Biopsy market has been segmented into:
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Others

By Application, Circulating Biomarker for Liquid Biopsy has been segmented into:
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring Orthopedics

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Circulating Biomarker for Liquid Biopsy market presented in the report. This section sheds light on the sales growth of different regional and country-level Circulating Biomarker for Liquid Biopsy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Circulating Biomarker for Liquid Biopsy market.

The report offers in-depth assessment of the growth and other aspects of the Circulating Biomarker for Liquid Biopsy market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Circulating Biomarker for Liquid Biopsy Market Share Analysis
Circulating Biomarker for Liquid Biopsy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Circulating Biomarker for Liquid Biopsy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Circulating Biomarker for Liquid Biopsy sales, revenue and market share for each player covered in this report.

The major players covered in Circulating Biomarker for Liquid Biopsy are:
Abbott Laboratories
Fluxion Biosciences
Epigenomics AG
Becton, Dickinson and Company
Affymetrix
GE Healthcare
Biocept
Agilent Technologies

レポート目次

---

Table of Contents

1 Circulating Biomarker for Liquid Biopsy Market Overview
1.1 Product Overview and Scope of Circulating Biomarker for Liquid Biopsy
1.2 Classification of Circulating Biomarker for Liquid Biopsy by Type
1.2.1 Global Circulating Biomarker for Liquid Biopsy Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Type in 2019
1.2.3 Circulating Tumor Cells (CTCs)
1.2.4 Circulating Tumor DNA (ctDNA)
1.2.5 Cell-Free DNA (cfDNA)
1.2.6 Extracellular Vesicles (EVs)
1.2.7 Others
1.3 Global Circulating Biomarker for Liquid Biopsy Market by Application
1.3.1 Overview: Global Circulating Biomarker for Liquid Biopsy Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Early Cancer Screening
1.3.3 Therapy Selection
1.3.4 Treatment Monitoring
1.3.5 Recurrence Monitoring Orthopedics
1.4 Global Circulating Biomarker for Liquid Biopsy Market by Regions
1.4.1 Global Circulating Biomarker for Liquid Biopsy Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Circulating Biomarker for Liquid Biopsy (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Circulating Biomarker for Liquid Biopsy Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Circulating Biomarker for Liquid Biopsy Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Circulating Biomarker for Liquid Biopsy Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Circulating Biomarker for Liquid Biopsy Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Circulating Biomarker for Liquid Biopsy Status and Prospect (2015-2025)
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Abbott Laboratories SWOT Analysis
2.1.4 Abbott Laboratories Product and Services
2.1.5 Abbott Laboratories Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Fluxion Biosciences
2.2.1 Fluxion Biosciences Details
2.2.2 Fluxion Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Fluxion Biosciences SWOT Analysis
2.2.4 Fluxion Biosciences Product and Services
2.2.5 Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.3 Epigenomics AG
2.3.1 Epigenomics AG Details
2.3.2 Epigenomics AG Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Epigenomics AG SWOT Analysis
2.3.4 Epigenomics AG Product and Services
2.3.5 Epigenomics AG Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Becton, Dickinson and Company
2.4.1 Becton, Dickinson and Company Details
2.4.2 Becton, Dickinson and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Becton, Dickinson and Company SWOT Analysis
2.4.4 Becton, Dickinson and Company Product and Services
2.4.5 Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.5 Affymetrix
2.5.1 Affymetrix Details
2.5.2 Affymetrix Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Affymetrix SWOT Analysis
2.5.4 Affymetrix Product and Services
2.5.5 Affymetrix Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.6 GE Healthcare
2.6.1 GE Healthcare Details
2.6.2 GE Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 GE Healthcare SWOT Analysis
2.6.4 GE Healthcare Product and Services
2.6.5 GE Healthcare Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Biocept
2.7.1 Biocept Details
2.7.2 Biocept Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Biocept SWOT Analysis
2.7.4 Biocept Product and Services
2.7.5 Biocept Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
2.8 Agilent Technologies
2.8.1 Agilent Technologies Details
2.8.2 Agilent Technologies Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Agilent Technologies SWOT Analysis
2.8.4 Agilent Technologies Product and Services
2.8.5 Agilent Technologies Circulating Biomarker for Liquid Biopsy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Circulating Biomarker for Liquid Biopsy Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Circulating Biomarker for Liquid Biopsy Players Market Share
3.2.2 Top 10 Circulating Biomarker for Liquid Biopsy Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Circulating Biomarker for Liquid Biopsy Revenue and Market Share by Regions
4.2 North America Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
4.3 Europe Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
4.5 South America Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
5 North America Circulating Biomarker for Liquid Biopsy Revenue by Countries
5.1 North America Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
5.2 USA Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
5.3 Canada Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
5.4 Mexico Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
6 Europe Circulating Biomarker for Liquid Biopsy Revenue by Countries
6.1 Europe Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
6.2 Germany Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
6.3 UK Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
6.4 France Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
6.5 Russia Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
6.6 Italy Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue by Countries
7.1 Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
7.2 China Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
7.3 Japan Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
7.4 Korea Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
7.5 India Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
8 South America Circulating Biomarker for Liquid Biopsy Revenue by Countries
8.1 South America Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
8.2 Brazil Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
8.3 Argentina Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Circulating Biomarker for Liquid Biopsy by Countries
9.1 Middle East & Africa Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
9.2 Saudi Arabia Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
9.3 UAE Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
9.4 Egypt Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
9.5 South Africa Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Circulating Biomarker for Liquid Biopsy Revenue and Market Share by Type (2015-2020)
10.2 Global Circulating Biomarker for Liquid Biopsy Market Forecast by Type (2019-2024)
10.3 Circulating Tumor Cells (CTCs) Revenue Growth Rate (2015-2025)
10.4 Circulating Tumor DNA (ctDNA) Revenue Growth Rate (2015-2025)
10.5 Cell-Free DNA (cfDNA) Revenue Growth Rate (2015-2025)
10.6 Extracellular Vesicles (EVs) Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Circulating Biomarker for Liquid Biopsy Market Segment by Application
11.1 Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Application (2015-2020)
11.2 Circulating Biomarker for Liquid Biopsy Market Forecast by Application (2019-2024)
11.3 Early Cancer Screening Revenue Growth (2015-2020)
11.4 Therapy Selection Revenue Growth (2015-2020)
11.5 Treatment Monitoring Revenue Growth (2015-2020)
11.6 Recurrence Monitoring Orthopedics Revenue Growth (2015-2020)
12 Global Circulating Biomarker for Liquid Biopsy Market Size Forecast (2021-2025)
12.1 Global Circulating Biomarker for Liquid Biopsy Market Size Forecast (2021-2025)
12.2 Global Circulating Biomarker for Liquid Biopsy Market Forecast by Regions (2021-2025)
12.3 North America Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
12.4 Europe Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
12.6 South America Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Circulating Biomarker for Liquid Biopsy Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Circulating Biomarker for Liquid Biopsy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Circulating Biomarker for Liquid Biopsy Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Circulating Biomarker for Liquid Biopsy Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Abbott Laboratories Corporate Information, Location and Competitors
Table 6. Abbott Laboratories Circulating Biomarker for Liquid Biopsy Major Business
Table 7. Abbott Laboratories Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 8. Abbott Laboratories SWOT Analysis
Table 9. Abbott Laboratories Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 10. Abbott Laboratories Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Fluxion Biosciences Corporate Information, Location and Competitors
Table 12. Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Major Business
Table 13. Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2018-2019)
Table 14. Fluxion Biosciences SWOT Analysis
Table 15. Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 16. Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Epigenomics AG Corporate Information, Location and Competitors
Table 18. Epigenomics AG Circulating Biomarker for Liquid Biopsy Major Business
Table 19. Epigenomics AG Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 20. Epigenomics AG SWOT Analysis
Table 21. Epigenomics AG Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 22. Epigenomics AG Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Becton, Dickinson and Company Corporate Information, Location and Competitors
Table 24. Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Major Business
Table 25. Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 26. Becton, Dickinson and Company SWOT Analysis
Table 27. Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 28. Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Affymetrix Corporate Information, Location and Competitors
Table 30. Affymetrix Circulating Biomarker for Liquid Biopsy Major Business
Table 31. Affymetrix Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 32. Affymetrix SWOT Analysis
Table 33. Affymetrix Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 34. Affymetrix Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. GE Healthcare Corporate Information, Location and Competitors
Table 36. GE Healthcare Circulating Biomarker for Liquid Biopsy Major Business
Table 37. GE Healthcare Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 38. GE Healthcare SWOT Analysis
Table 39. GE Healthcare Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 40. GE Healthcare Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Biocept Corporate Information, Location and Competitors
Table 42. Biocept Circulating Biomarker for Liquid Biopsy Major Business
Table 43. Biocept Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 44. Biocept SWOT Analysis
Table 45. Biocept Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 46. Biocept Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Agilent Technologies Corporate Information, Location and Competitors
Table 48. Agilent Technologies Circulating Biomarker for Liquid Biopsy Major Business
Table 49. Agilent Technologies Circulating Biomarker for Liquid Biopsy Total Revenue (USD Million) (2017-2018)
Table 50. Agilent Technologies SWOT Analysis
Table 51. Agilent Technologies Circulating Biomarker for Liquid Biopsy Product and Solutions
Table 52. Agilent Technologies Circulating Biomarker for Liquid Biopsy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) by Players (2015-2020)
Table 54. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Players (2015-2020)
Table 55. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) by Regions (2015-2020)
Table 56. Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Regions (2015-2020)
Table 57. North America Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
Table 58. North America Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Table 59. Europe Circulating Biomarker for Liquid Biopsy Revenue (Million USD) by Countries (2015-2020)
Table 60. Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue (Million USD) by Countries (2015-2020)
Table 61. South America Circulating Biomarker for Liquid Biopsy Revenue by Countries (2015-2020)
Table 62. South America Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Table 63. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue (Million USD) by Countries (2015-2020)
Table 64. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Table 65. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) by Type (2015-2020)
Table 66. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Type (2015-2020)
Table 67. Global Circulating Biomarker for Liquid Biopsy Revenue Forecast by Type (2021-2025)
Table 68. Global Circulating Biomarker for Liquid Biopsy Revenue by Application (2015-2020)
Table 69. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Application (2015-2020)
Table 70. Global Circulating Biomarker for Liquid Biopsy Revenue Forecast by Application (2021-2025)
Table 71. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Circulating Biomarker for Liquid Biopsy Picture
Figure 2. Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Type in 2019
Figure 3. Circulating Tumor Cells (CTCs) Picture
Figure 4. Circulating Tumor DNA (ctDNA) Picture
Figure 5. Cell-Free DNA (cfDNA) Picture
Figure 6. Extracellular Vesicles (EVs) Picture
Figure 7. Others Picture
Figure 8. Circulating Biomarker for Liquid Biopsy Revenue Market Share by Application in 2019
Figure 9. Early Cancer Screening Picture
Figure 10. Therapy Selection Picture
Figure 11. Treatment Monitoring Picture
Figure 12. Recurrence Monitoring Orthopedics Picture
Figure 13. Global Circulating Biomarker for Liquid Biopsy Revenue (USD Million) and Growth Rate (2015-2025)
Figure 14. North America Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Europe Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. South America Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Players in 2019
Figure 21. Global Top 5 Players Circulating Biomarker for Liquid Biopsy Revenue Market Share in 2019
Figure 22. Global Top 10 Players Circulating Biomarker for Liquid Biopsy Revenue Market Share in 2019
Figure 23. Key Players Market Share Trend
Figure 24. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 25. Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Regions (2015-2020)
Figure 26. Global Circulating Biomarker for Liquid Biopsy Revenue Market Share by Regions in 2018
Figure 27. North America Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 28. Europe Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 29. Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 30. South America Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 31. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 32. North America Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Figure 33. North America Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries in 2019
Figure 34. USA Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 35. Canada Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 36. Mexico Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 37. Europe Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Figure 38. Europe Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries in 2019
Figure 39. Germany Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 40. UK Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 41. France Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 42. Russia Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 43. Italy Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Figure 45. Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries in 2019
Figure 46. China Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 47. Japan Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 48. Korea Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 49. India Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 50. Southeast Asia Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 51. South America Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Figure 52. South America Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries in 2019
Figure 53. Brazil Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 54. Argentina Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 55. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries (2015-2020)
Figure 56. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue Market Share by Countries in 2019
Figure 57. Saudi Arabia Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 58. UAE Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 59. Egypt Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 60. South Africa Circulating Biomarker for Liquid Biopsy Revenue and Growth Rate (2015-2020)
Figure 61. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Type (2015-2020)
Figure 62. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Type in 2019
Figure 63. Global Circulating Biomarker for Liquid Biopsy Market Share Forecast by Type (2021-2025)
Figure 64. Global Circulating Tumor Cells (CTCs) Revenue Growth Rate (2015-2020)
Figure 65. Global Circulating Tumor DNA (ctDNA) Revenue Growth Rate (2015-2020)
Figure 66. Global Cell-Free DNA (cfDNA) Revenue Growth Rate (2015-2020)
Figure 67. Global Extracellular Vesicles (EVs) Revenue Growth Rate (2015-2020)
Figure 68. Global Others Revenue Growth Rate (2015-2020)
Figure 69. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Application (2015-2020)
Figure 70. Global Circulating Biomarker for Liquid Biopsy Revenue Share by Application in 2019
Figure 71. Global Circulating Biomarker for Liquid Biopsy Market Share Forecast by Application (2021-2025)
Figure 72. Global Early Cancer Screening Revenue Growth Rate (2015-2020)
Figure 73. Global Therapy Selection Revenue Growth Rate (2015-2020)
Figure 74. Global Treatment Monitoring Revenue Growth Rate (2015-2020)
Figure 75. Global Recurrence Monitoring Orthopedics Revenue Growth Rate (2015-2020)
Figure 76. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 77. Global Circulating Biomarker for Liquid Biopsy Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 78. Global Circulating Biomarker for Liquid Biopsy Revenue Market Share Forecast by Regions (2021-2025)
Figure 79. North America Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
Figure 80. Europe Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
Figure 81. Asia-Pacific Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
Figure 82. South America Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
Figure 83. Middle East and Africa Circulating Biomarker for Liquid Biopsy Revenue Market Forecast (2021-2025)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel

---